Saturday’s Daily Piece: Cardiovascular Benefit with Liraglutide Likely Mediated by A1c

Liraglutide (Victoza), GLP-1 receptor agonist, is known for its ability to lower cardiovascular risk in persons with type 2 diabetes who have blood glucose values consistently above target range and who at high risk for a cardiovascular event (i.e. heart attack). What exactly mediates this benefit? Buse and colleagues uncovered that this benefit most likely is mediated by hemoglobin A1c. Please click below for additional details on this exploratory analysis.

https://www.healio.com/endocrinology/diabetes/news/online/%7B09ebef6b-62b1-42d0-bbf0-3c2ed5e6b68c%7D/hba1c-likely-mediates-liraglutides-cv-benefit?M_BT=4557970002905

When Changing from Daily to Weekly GLP-1, Make Sure Patient is Clear
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#A1c #liraglutide #CV #benefit

Please share your thoughts and subscribe to receive my blogs.

Leave a Reply

Your email address will not be published. Required fields are marked *